AEterna Zentaris's lead drug fails second Phase III trial in BPH
This article was originally published in Scrip
Executive Summary
The future of AEterna Zentaris's lead drug candidate cetrorelix has been left in doubt after it failed to meet the primary endpoint of its second Phase III trial in benign prostate hyperplasia (BPH).